North America Inherited Retinal Diseases Market, By Disease Type (Retinitis Pigmentosa, Stargardt’s Disease, Achromatopsia, Cone-Rod Dystrophy, Choroideremia, Leber Congenital Amaurosis, Macular Edema, and Others), By Type (Diagnosis and Therapy), End-Users (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Retail Sales and Direct Tender) Industry Trends and Forecast to 2029.
Market Analysis and Insights : North America Inherited Retinal Diseases Market
Inherited retinal diseases-or IRDs-are a group of diseases that can cause severe vision loss or even blindness. Each IRD is caused by at least one gene that is not working as it should. IRDs can affect individuals of all ages, can progress at different rates, and are rare. However, many are degenerative, which means that the symptoms of the disease will get worse over time. Common types of IRDs include Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa, Choroideremia, Stargardt’s Disease, and Achromatopsia. The goal of gene therapy is to correct or compensate for the faulty gene. IRDs are especially strong candidates for gene therapy treatments, due to the retina’s unique physical makeup. Compared to other organs of the body, the eye is small and easy to access for treatment administration. However, certain areas of the body are immune privileged, which means that the normal immune response isn’t as active. This is typically in areas of our bodies that are very important, and may become damaged if swelling or inflammation occurs. This means that anything that is implanted into the eye-a cell with a corrected gene, for instance-is less likely to be rejected.
The diagnosis and treatment of inherited retinal diseases consist of various techniques that allow diagnosis of inherited retinal disease after the approval of the product. The treatment for the disease is recently approved which support the market growth.
The inherited retinal diseases is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the inherited retinal diseases market will grow at a CAGR of 7.6% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Disease Type (Retinitis Pigmentosa, Stargardt’s Disease, Achromatopsia, Cone-Rod Dystrophy, Choroideremia, Leber Congenital Amaurosis, Macular Edema, and Others), By Type (Diagnosis and Therapy), End-Users (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Retail Sales and Direct Tender) |
|
Countries Covered |
U.S., Canada and Mexico in North America |
|
Market Players Covered |
Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies |
Inherited Retinal Diseases Market Dynamics
Drivers
- Increase in the prevalence of Inherited Retinal Diseases
The increasing prevalence and continuous discovery of new mutagenic sites that are genetically transmitted are expected to act as a driver for the growth of the market. The prevalence of monogenic IRDs is approximately 1 in 2000 affecting two million people online.
- Increasing in Pipeline Products
As clinical trial activity rises to new levels, the field appears poised to make rapid and important advances in IRD research and patient care. These are only a few common trials, thus, the companies operating in this market continuously do clinical trials and put their candidates in clinical trials. This is expected to create an opportunity and fuel the North America inherited retinal diseases market.High prevalence of genetic conditions
Also, the increase in the prevalence rate of some genetic conditions such as Miller-Dieker syndrome and Walker-Warburg syndrome will further enhance the growth of inherited retinal diseases market.
Furthermore, Increase in strategic initiatives by key players, advancement in medical technology, increasing product approval for IRDs, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the inherited retinal diseases market. Other factors such as increase in the demand for effective therapies and rising adoption rate for early genetic counselling will positively impact the inherited retinal diseases market's growth rate. Additionally, high disposable income, rising number of cases of various retinal diseases will result in the expansion of inherited retinal diseases market.
Opportunities
- Increase in Government Initiatives Towards Inherited Retinal Disease.
Moreover, the increase in awarenss and treatment seeking rate and emerging reimbursent policies for the treatment will boost new opportunities for the market's growth rate.
Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the inherited retinal diseases market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate inherited retinal diseases market in future.
Restraints/Challenges
However, high cost associated with the available treatment and lack of infrastructure in low-income countries will impede the growth rate of inherited retinal diseases market. Additionally, lack of enough qualified professionals, and complications involved with the disease will hinder the inherited retinal diseases market growth.
This inherited retinal diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Inherited retinal diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Inherited retinal disease is a genetic disorder that is relatively uncommon and whose incidence is unknown. According to a study of inherited retinal diseases the prevalence of IRD’s is 1 in 3000.
Retinitis pigmentosa is the most common disorder among the other disorders. Retinitis pigmentosa is a group of related eye disorders caused by variations in 60 genes that affect the retina. IRDs are a heterogeneous group of orphan eye diseases with a prevalence estimated at between 0.06% and 0.2%, with a North America IRD caseload in the range of 5–10 million individuals.
Inherited retinal diseases market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Post COVID-19 Impact on Inherited Retinal Diseases Market
The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.
Recent Development
- In January 2022, the world's leading organization committed to finding treatments and cures for blinding retinal diseases, has announced the launch of the Diana Davis Spencer Foundation Enhanced Translational Research Acceleration Program.
North America Inherited Retinal Diseases Market Scope
The inherited retinal diseases market is segmented into disease type, type, end-user and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Disease Type
- Retinitis Pigmentosa
- Stargardt’s Disease
- Achromatopsia
- Cone-Rod Dystrophy
- Choroideremia
- Leber Congenital Amaurosis (LCA)
- Macular Edema
- Others
On the basis of type, the inherited retinal diseases market is segmented into disease type (retinitis pigmentosa, stargardt’s disease, achromatopsia, cone-rod dystrophy, choroideremia, leber congenital amaurosis, macular edema, and others
Type
- Diagnosis
- Therapy
On the basis of type, the inherited retinal diseases market is segmented into diagnosis and therapy. The diagnosis segment is sub-segmented into gene therapy, retinal prosthetic, neuroprotective agents, others. The neuroprotective agents are further sub-segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, others. The diagnosis segment is segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further sub-segmented into retinal imaging, electrophysiological tests, visual field test and clinical eye examination. Retinal imaging is further segmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO), adaptive optics (AO) imaging and conventional color fundus imaging. Electrophysiological tests are further segmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Visual field test is further segmented into computerized visual field tests and manual field test. Clinical Eye examination is segmented into slit lamp, indirect ophthalmoscopy, refraction test, dilation exam
End User
- Hospitals
- Specialty Clinics
- Ambulatory surgical center
- Home Healthcare
- Others
On the basis of end-users, the inherited retinal diseases market is segmented into hospitals, specialty clinics, ambulatory surgical center, home healthcare and others
Distribution Channel
- Retail Sales
- Direct Tender
The inherited retinal diseases market is also segmented on the basis of distribution channel into retail sales, direct tender.
Pipeline Analysis
The pipeline analysis of inherited retinal diseases drugs includes various pipeline therapies such as NCT05244304, NCT00999609, NCT05176717, NCT05158296, NCT04850118. Belite Bio, Inc, Spark Therapeutics, ProQR Therapeutics, Applied Genetic Technologies Corp, Biogen, MeiraGTx Ltd are involved in the development of potential drugs for the improvement of treatment of seizures.
Inherited Retinal Diseases Market Regional Analysis/Insights
The inherited retinal diseases market is analysed and market size insights and trends are provided by country, disease type, type, end-user and distribution channel as referenced above.
The countries covered in the inherited retinal diseases market report are U.S., Canada and Mexico in North America.
U.S. dominates the inherited retinal diseases market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Inherited Retinal Diseases Market Share Analysis
The inherited retinal diseases market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on inherited retinal diseases market.
Some of the major players operating in the inherited retinal diseases market are Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies among others.
Research Methodology: North America Inherited Retinal Diseases Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report.. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, North AmericaVsRegional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA INHERITED RETINAL DISEASES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS FOR NORTH AMERICA INHERITED RETINAL DISEASES MARKET
5 REGULATORY FRAMEWORK
6 PREMIUM INSIGHTS
6.1 PESTEL ANALYSIS
6.2 POTER’S FIVE FORCES MODEL
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES
7.1.2 INCREASE IN PIPELINE PRODUCTS
7.1.3 INCREASING PRODUCT APPROVAL FOR INHERITED RETINAL DISEASES
7.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER
7.2 RESTRAINTS
7.2.1 HIGH COST OF TREATMENT AND PROCEDURES
7.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
7.3 OPPORTUNITIES
7.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARDS INHERITED RETINAL DISEASES(IRDS)
7.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE
7.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
7.4 CHALLENGES
7.4.1 RISKS ASSOCIATED WITH IRD SPECIFIC GENE THERAPY
7.4.2 LIMITED ACCESS TO TREATMENT
8 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE
8.1 OVERVIEW
8.2 RETINITIS PIGMENTOSA
8.3 STARGARDT’S DISEASE
8.4 ACHROMATOPSIA
8.5 CONE-ROD DYSTROPHY
8.6 CHOROIDEREMIA
8.7 LEBER CONGENITAL AMAUROSIS (LCA)
8.8 MACULAR EDEMA
8.9 OTHERS
9 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIAGNOSIS
9.2.1 CLINICAL DIAGNOSIS
9.2.1.1 RETINAL IMAGING
9.2.1.1.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)
9.2.1.1.2 FUNDUS AUTOFLUORESCENCE IMAGING (FAF)
9.2.1.1.3 SCANNING LASER OPHTHALMOSCOPY (SLO)
9.2.1.1.4 ADAPTIVE OPTICS (AO) IMAGING
9.2.1.1.5 CONVENTIONAL COLOR FUNDUS IMAGING
9.2.1.2 ELECTROPHYSIOLOGICAL TESTS
9.2.1.2.1 FULL-FIELD ELECTRORETINOGRAM (ERG)
9.2.1.2.2 DARK ADAPTOMETRY (DA)
9.2.1.3 VISUAL FIELD TEST
9.2.1.3.1 COMPUTERIZED VISUAL FIELD TESTS
9.2.1.3.2 MANUAL FIELD TEST
9.2.1.4 CLINICAL EYE EXAMINATION
9.2.1.4.1 SLIT LAMP
9.2.1.4.2 INDIRECT OPHTHALMOSCOPY
9.2.1.4.3 REFRACTION TEST
9.2.1.4.4 DILATION EXAM
9.2.1.5 OTHERS
9.2.2 GENETIC DIAGNOSIS
9.3 THERAPY
9.3.1 GENE THERAPY
9.3.2 RETINAL PROSTHETIC
9.3.3 NEUROPROTECTIVE AGENTS
9.3.3.1 VITAMIN A PALMITATE
9.3.3.2 DOCOSAHEXAENOIC ACID
9.3.3.3 LUTEIN
9.3.3.4 OTHERS
9.3.4 OTHERS
10 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 SPECIALTY CLINICS
10.4 AMBULATORY SURGICAL CENTERS
10.5 HOME HEALTHCARE
10.6 OTHERS
11 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 RETAIL SALES
11.2.1 HOSPITAL PHARMACIES
11.2.2 RETAIL PHARMACIES
11.2.3 OTHERS
11.3 DIRECT TENDER
12 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 SPARK THERAPEUTICS, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENTS
15.1.4.1 PROGRAM LAUNCH
15.1.4.2 ACQUISITIONS
15.2 NOVARTIS AG
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.2.5.1 AGREEMENT
15.3 OKUVISION
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.3.4.1 EXPANSION
15.3.4.2 EVENTS
15.3.4.3 APPROVAL
15.4 NIDEK CO., LTD
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENTS
15.4.4.1 PRODUCT LAUNCH
15.4.4.2 PRODUCT LAUNCH
15.5 INVITAE CORPORATION
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.5.5.1 PROGRAM LAUNCH
15.5.5.2 ACQUISITION
15.6 ZEISS INTERNATIONAL
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.6.4.1 EVENTS
15.6.4.2 SOCIAL INVOLVEMENT
15.7 OPTOS (A SUBSIDIARY OF NIKON CORPORATION)
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENTS
15.8 NEUROSOFT
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 ASTELLAS PHARMA INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 BIONIC VISION TECHNOLOGIES
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.10.3.1 AWARD
15.11 COAVE THERAPEUTICS
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.11.3.1 AGREEMENT
15.12 GENSIGHT BIOLOGICS
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.12.4.1 EVENT
15.12.4.2 AWARD
15.13 IONIS PHARMACEUTICALS
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.13.4.1 EVENT
15.14 IVERIC BIO
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 JOHNSON &JOHNSON SERVICES, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.15.4.1 COLLABORATION
15.16 LKC TECHNOLOGIES, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.16.3.1 PRODUCT LAUNCH
15.17 MEIRAGTX LIMITED
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENTS
15.17.3.1 EVENTS
15.17.3.2 AWARD
15.17.3.3 COLLABORATION
15.18 OCUGEN INC.
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
15.18.3.1 INVESTMENT
15.18.3.2 CLINICAL TRIAL
15.19 PIXIUM VISION
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.19.4.1 AWARD
15.2 PROQR THERAPEUTICS
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.20.3.1 EVENT
15.21 SECOND SIGHT
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENT
15.21.3.1 PRODUCT LAUNCH
15.22 SPARING VISION
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENT
15.22.3.1 ACQUISITION
15.23 REGENXBIO INC.
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENTS
15.23.3.1 EVENT
15.23.3.2 COLLABORATION
15.23.3.3 CERTIFICATION
15.24 RENEURON GROUP PLC
15.24.1 COMPANY SNAPSHOT
15.24.2 PRODUCT PORTFOLIO
15.24.3 RECENT DEVELOPMENT
15.24.3.1 STRATEGIC INITIATIVE
16 QUESTIONNAIRE
17 RELATED REPORTS
Lista de Tablas
TABLE 1 PIPELINE ANALYSIS FOR INHERITED RETINAL DISEASES:
TABLE 2 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA RETINITIS PIGMENTOSA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA STARGARDT’S DISEASE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA ACHROMATOPSIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA CONE-ROD DYSTROPHY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA CHOROIDERMIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA LEBER CONGENITAL AMAUROSIS (LCA) IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA MACULAR EDEMA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA ELECTROPHYSIOLOGICAL TETS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA HOSPITALS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA SPECIALTY CLINICS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA HOME HEALTHCARE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA DIRECT TENDER IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 46 U.S. INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 47 U.S. INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 U.S. THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 U.S. NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 U.S. DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 U.S. CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 U.S. RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 U.S. ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 U.S. VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 U.S. CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 U.S. INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 57 U.S. INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 58 U.S. RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 59 CANADA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 60 CANADA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 CANADA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 CANADA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 CANADA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 CANADA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 CANADA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 CANADA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 CANADA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 CANADA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 CANADA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 CANADA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 CANADA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 MEXICO INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 73 MEXICO INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 MEXICO THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 MEXICO NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 MEXICO DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 MEXICO CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 MEXICO RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 MEXICO ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 MEXICO VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 MEXICO CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 MEXICO INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 83 MEXICO INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 MEXICO RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
Lista de figuras
FIGURE 1 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN NORTH AMERICA INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE NORTH AMERICA INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 RETINITIS PIGMENTOSA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA INHERITED RETINAL DISEASES MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA INHERITED RETINAL DISEASES MARKET
FIGURE 16 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2021
FIGURE 17 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2020-2029 (USD MILLION)
FIGURE 18 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY TYPE, 2021
FIGURE 21 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 22 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY END USER, 2021
FIGURE 25 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 26 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY END USER, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 29 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 30 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 31 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: SNAPSHOT (2021)
FIGURE 33 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021)
FIGURE 34 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 35 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 36 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 37 NORTH AMERICA INHERITED RETINAL DISEASES MARKET: COMPANY SHARE 2021 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
